Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group.

BACKGROUND Long-term follow-up in patients treated with thrombolysis for acute myocardial infarction thus far has been reported in a few studies only, and no long-term follow-up is available for patients who underwent additional percutaneous transluminal coronary angioplasty (PTCA). This report describes 5-year survival as collected in patients who received placebo, recombinant tissue plasminogen activator (rTPA), or rTPA with additional immediate PTCA in two European Cooperative Study Group trials. Determinants for long-term survival were assessed in 1043 patients discharged alive. METHODS AND RESULTS Five-year follow-up information on mortality was collected. Hospital mortality was lower after rTPA than placebo (2.5% versus 5.7%, P = .04) and higher after rTPA with immediate PTCA compared with rTPA without additional intervention (6.0% versus 2.2%, P = .07). Of the 1043 hospital survivors, data were available for 923 patients, of whom 109 died. In the placebo group, mortality after hospital discharge was 10.7% versus 11.0% in the comparative rTPA group. The patients treated with rTPA and immediate PTCA had a mortality rate of 10.5% versus 8.9% in the rTPA group without PTCA (all P = NS). Significant determinants of mortality in multivariate proportional hazards analysis were enzymatic infarct size, indicators of residual left ventricular function, number of diseased vessels and TIMI perfusion grade at discharge. Patients with TIMI grade 2 flow had mortality rates similar to those with TIMI flow grades 0 and 1, while prognosis was better in patients with TIMI flow grade 3. CONCLUSIONS The initial in-hospital benefit of thrombolysis with intravenous rTPA is maintained throughout 5 years, with no early or late beneficial effect of systematic immediate PTCA. Enzymatic infarct size, left ventricular function, and extent of coronary artery disease are predictors for long-term survival. TIMI perfusion grade 2 at discharge should be considered as an inadequate result of therapy.

[1]  E. Braunwald,et al.  Two- and three-year results of the thrombolysis in myocardial infraction (TIMI) phaes II clinical trial , 1993 .

[2]  M. Simoons,et al.  Tailored Thrombolytic Therapy A Perspective , 1993, Circulation.

[3]  J. Reiber,et al.  A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. , 1993, The New England journal of medicine.

[4]  J O'Keefe,et al.  A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction , 1993 .

[5]  F. Van de Werf,et al.  Prediction of mortality following hospital discharge after thrombolysis for acute myocardial infarction: is there a need for coronary angiography? European Cooperative Study Group. , 1993, European heart journal.

[6]  F. Van de Werf,et al.  Recombinant Tissue‐Type Plasminogen Activator and Immediate Angioplasty in Acute Myocardial Infarction: One‐Year Follow‐up , 1992, Circulation.

[7]  E. Braunwald,et al.  One‐Year Results of the Thrombolysis in Myocardial Infarction Investigation (TIMI) Phase II Trial , 1992, Circulation.

[8]  J. Anderson,et al.  Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. , 1992, Journal of the American College of Cardiology.

[9]  J. Tijssen,et al.  Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands. , 1989, Journal of the American College of Cardiology.

[10]  F. Van de Werf,et al.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.

[11]  H. Lambertz,et al.  THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.

[12]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  LONG-TERM EFFECTS OF INTRAVENOUS THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION: FINAL REPORT OF THE GISSI STUDY , 1987, The Lancet.

[13]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[14]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[15]  M. Simoons,et al.  IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION A Randomised Trial by the Interuniversity Cardiology Institute in The Netherlands , 1985, The Lancet.

[16]  J L Ritchie,et al.  The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. , 1985, The New England journal of medicine.

[17]  M. Weinstein,et al.  Clinical Decision Analysis , 1980 .

[18]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[19]  A. Muijtjens,et al.  Estimation of circulatory parameters in patients with acute myocardial infarction. Significance for calculation of enzymatic infarct size. , 1979, Cardiovascular research.